SCHEMBL965294

SCHEMBL965294

Cc1ccc(S(=O)(=O)NC(=O)/C=C/c2c(C)nn(C)c2-n2cc(Cl)c3cccnc32)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.41
ENPP3 O14638 3/20 0.41
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
MAPT P10636 1/20 0.39
PTGS2 P35354 3/20 0.39
SLC40A1 Q9NP59 1/20 0.38
NPC1 O15118 2/20 0.38
HSP90AA1 P07900 1/20 0.38
RAB9A P51151 1/20 0.38
ADAM17 P78536 1/20 0.38
KLF5 Q13887 1/20 0.38
HDAC4 P56524 4/20 0.36
HDAC1 Q13547 4/20 0.36
HDAC8 Q9BY41 3/20 0.36
TDP1 Q9NUW8 3/20 0.36
ELANE P08246 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL965295 1.00 EGFR (0.41) EGFRENPP3MEN1KMT2AMAPT
SCHEMBL963601 0.91 ENPP3 (0.42) EGFRENPP3MEN1KMT2AMAPT
SCHEMBL963599 0.91 ENPP3 (0.42) EGFRENPP3MEN1KMT2AMAPT
SCHEMBL5126136 0.89 ELANE (0.36) MAPTNPC1RAB9AHDAC4HDAC1
SCHEMBL5126154 0.89 ELANE (0.36) MAPTNPC1RAB9AHDAC4HDAC1
SCHEMBL965832 0.87 GLO1 (0.37) MAPTHDAC4HDAC1HDAC8ELANE
SCHEMBL965833 0.87 GLO1 (0.37) MAPTHDAC4HDAC1HDAC8ELANE
SCHEMBL963249 0.83 ENPP3 (0.54) EGFRENPP3MEN1KMT2AMAPT
SCHEMBL963247 0.83 ENPP3 (0.54) EGFRENPP3MEN1KMT2AMAPT
SCHEMBL963133 0.83 L3MBTL1 (0.48) MAPTNPC1RAB9AELANEALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009384-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-01-13 US disclosed
EP-2118066-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA Takeda Pharmaceutical Company Limited (JP) 2009-11-18 EP disclosed
WO-2008099794-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-08-21 WO disclosed
US-20080194617-A1 Fused ring compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194617-A1 Fused ring compound SLC5A1, SLC5A2, GPR119 EGFR 4255/4885ENPP3 1924/4885MEN1 1234/4885
US-20110009384-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA PPARA, PPARD, PPARG EGFR 1873/4885ENPP3 2208/4885MEN1 4766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.